title: Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma.
abstract: A simple, rapid, and selective HPLC-UV method was developed for the determination of antihypertensive drug substances: amlodipine besilat (AML), olmesartan medoxomil (OLM), valsartan (VAL), and hydrochlorothiazide (HCT) in pharmaceuticals and plasma. These substances are mostly used as combinations. The combinations are found in various forms, especially in current pharmaceuticals as threesome components: OLM, AML, and HCT (combination I) and AML, VAL, and HCT (combination II). The separation was achieved by using an RP-CN column, and acetonitrile-methanol-10 mmol orthophosphoric acid pH 2.5 (7 : 13 : 80, v/v/v) was used as a mobile phase; the detector wavelength was set at 235 nm. The linear ranges were found as 0.1-18.5  μ g/mL, 0.4-25.6  μ g/mL, 0.3-15.5  μ g/mL, and 0.3-22  μ g/mL for AML, OLM, VAL, and HCT, respectively. In order to check the selectivity of the method for pharmaceutical preparations, forced degradation studies were carried out. According to the validation studies, the developed method was found to be reproducible and accurate as shown by RSD ≤6.1%, 5.7%, 6.9%, and 4.6% and relative mean error (RME) ≤10.6%, 5.8%, 6.5%, and 6.8% for AML, OLM, VAL, and HCT, respectively. Consequently, the method was applied to the analysis of tablets and plasma of the patients using drugs including those substances.
authors: Department of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, 34093 Istanbul, Turkey.
authors: Serife Evrim
authors: SE
authors: Kepekci Tekkeli
references: J Pharm Biomed Anal. 2007 Mar 12;43(4):1540-5
references: 17174058
references: Drugs. 2002;62(13):1983-2005
references: 12215069
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):169-72
references: 16426905
references: Lancet. 2005 Jan 15-21;365(9455):217-23
references: 15652604
references: Adv Ther. 2009 Nov;26(11):1012-23
references: 20024680
references: J Chromatogr B Biomed Appl. 1996 Nov 8;686(1):77-83
references: 8953194
references: Am J Manag Care. 2005 Sep;11(7 Suppl):S220-7
references: 16180960
references: Contemp Clin Trials. 2011 Sep;32(5):710-6
references: 21586342
references: Hypertension. 2003 Dec;42(6):1206-52
references: 14656957
references: Biomed Chromatogr. 2007 Feb;21(2):169-75
references: 17221911
references: J Pharm Biomed Anal. 1992 Jul;10(7):541-5
references: 1420482
references: Biomed Chromatogr. 2009 Jun;23(6):615-22
references: 19277959
references: Blood Press. 2008;17(1):7-17
references: 18568687
references: J Chromatogr A. 1996 Apr 5;729(1-2):293-6
references: 9004952
references: Am Heart J. 2006 Jan;151(1):176-84
references: 16368314
references: Blood Press. 2007;16(2):80-6
references: 17612905
references: J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404
references: 12461301
references: N Engl J Med. 2008 Dec 4;359(23):2417-28
references: 19052124
references: Clin Exp Hypertens A. 1983;5(2):157-66
references: 6831743
references: Clin Ther. 2010 Jul;32(7):1252-69
references: 20678674
references: J Pharm Biomed Anal. 2006 May 3;41(2):644-8
references: 16413728
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):345-9
references: 11824822
references: J Mass Spectrom. 2006 May;41(5):593-605
references: 16541390
references: J Chromatogr A. 2002 Mar 8;949(1-2):49-60
references: 11999756
references: J Pharm Anal. 2011 Feb;1(1):32-38
references: 29403679
references: Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):91-6
references: 11112088
references: J Pharm Sci. 1984 Mar;73(3):359-61
references: 6716243
references: Biomed Chromatogr. 2005 Dec;19(10):751-60
references: 15856489
references: Br J Clin Pharmacol. 1994 May;37(5):401-4
references: 8054244
references: JAMA. 2003 Dec 3;290(21):2805-16
references: 14657064
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):190-7
references: 17602900